- Home
- MRNS vs MAIA Comparison
MRNS vs MAIA Comparison
Compare MRNS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- MAIA
- Stock Information
- Founded
- MRNS 2003
- MAIA 2018
- Country
- MRNS United States
- MAIA United States
- Employees
- MRNS N/A
- MAIA N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- MRNS Health Care
- MAIA Health Care
- Exchange
- MRNS Nasdaq
- MAIA Nasdaq
- Market Cap
- MRNS 29.9M
- MAIA 58.3M
- IPO Year
- MRNS 2014
- MAIA 2022
- Fundamental
- Price
- MRNS $0.54
- MAIA $2.21
- Analyst Decision
- MRNS Buy
- MAIA
- Analyst Count
- MRNS 12
- MAIA 0
- Target Price
- MRNS $4.28
- MAIA N/A
- AVG Volume (30 Days)
- MRNS 3.2M
- MAIA 452.9K
- Earning Date
- MRNS 03-04-2025
- MAIA 11-12-2024
- Dividend Yield
- MRNS N/A
- MAIA N/A
- EPS Growth
- MRNS N/A
- MAIA N/A
- EPS
- MRNS N/A
- MAIA N/A
- Revenue
- MRNS $31,466,000.00
- MAIA N/A
- Revenue This Year
- MRNS $14.97
- MAIA N/A
- Revenue Next Year
- MRNS $57.65
- MAIA N/A
- P/E Ratio
- MRNS N/A
- MAIA N/A
- Revenue Growth
- MRNS 1.63
- MAIA N/A
- 52 Week Low
- MRNS $0.22
- MAIA $0.99
- 52 Week High
- MRNS $10.50
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- MRNS 70.61
- MAIA 51.91
- Support Level
- MRNS $0.53
- MAIA $2.03
- Resistance Level
- MRNS $0.56
- MAIA $2.44
- Average True Range (ATR)
- MRNS 0.03
- MAIA 0.19
- MACD
- MRNS 0.02
- MAIA 0.03
- Stochastic Oscillator
- MRNS 94.94
- MAIA 46.03
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.